PRESS RELEASE
Launch of InfectoPharm France SAS
Third sales subsidiary for the German paediatrics specialist
Heppenheim, February 22, 2024 – InfectoPharm Arzneimittel und Consilium GmbH has set up a further European subsidiary – this time in France. Philippe Personne took up the position of General Manager of InfectoPharm France SAS on 1 January 2024. His team will be responsible for driving forward the commercial development of several products, especially oriented for paediatric indications, but not only. The German pharmaceutical manufacturer is planning to launch further products from its portfolio in Chaponnay/Lyon.
“The French market represents a crucial strategic element for us,” points out Dr Markus Rudolph, Managing Director of InfectoPharm: “We have been pursuing internationalisation as a key driver of our business development for some years now.”
The InfectoPharm Group already has branches in Austria and Italy. These distribute a proportion of the Group’s current portfolio of roughly 130 products. Besides paediatric medicine, InfectoPharm’s other areas of expertise include infectiology, pneumology, dermatology, ENT and allergology. The InfectoPharm Group has over 400 employees, and posts annual growth of roughly 10 per cent and sales of EUR 275 million (2023).
“We are delighted to have appointed Philippe Personne as General Manager. He has so much experience in the pharmaceutical industry,” says Florence Wiche, Head of Global Sales & International Business at InfectoPharm: “Philippe joined us early on, initially providing us with effective support during the start-up process.”
To the InfectoPharm website
_____________________________________________________
About InfectoPharm
InfectoPharm Arzneimittel und Consilium GmbH is a medium-sized, family-led German company focusing on the fields of pediatrics, dermatology, HNO and unique antibiotic treatment options. For 35 years, InfectoPharm has distinguished itself as a groundbreaking pioneer in various fields of indications. The portfolio currently comprises around 130 preparations with numerous innovations in the fields of pediatrics, dermatology, infectious diseases, pneumology and allergology, which are increasingly attracting international attention. The “consilium service” is available free of charge to specialists as a product-neutral advisory and knowledge transfer service.
The InfectoPharm Group is engaged in more than 30 international partnerships and is increasingly expanding into non-EU markets. Subsidiaries of the group in Austria, Italy and France operate with a selected part of the portfolio. The InfectoPharm Group further consists of two strategically matching German subsidiaries: Pädia GmbH offers a distinct pediatric OTC portfolio with about 27 prescription-free pharmaceuticals and Beyvers GmbH in Berlin is an internationally known full service-supplier for pharmaceuticals and cosmetics.
With more than 400 employees, the group generates annual sales of around 275 million euros (2023) and an average growth rate of 10 percent. InfectoPharm regularly receives awards from the medical profession, such as the “Golden Tablet” or currently as “Most Crisis-Proof Employer” from Creditreform.
